Dyne Therapeutics
Dyne Therapeutics

Dyne Therapeutics

Biotechnology
WebsiteInvestor RelationsSEC
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

$3.4B

Market Cap • 9/17/2026

2017

(9 years)

Founded

2020

(6 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

4,8

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

4,5

EPS

—

Market Cap

Market Cap

3,4B

EV

2,7B

EV/Revenue

0

EV/EBITDA

-5

EV/EBIT

-5

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-17,8%

Total Yield

-17,8%

Payout

0%

Retained Earnings

-1,7B

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

993,7%

Capex/OCF

-4,5%

SBC/OCF

—

% PPE

4,5%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

40,7%

CAGR Net Income 5Y

39,7%

CAGR EPS 5Y

-2,2%

CAGR OCF 5Y

37,7%

Leverage

N.D./EBITDA

1,3

Debt/Equity

0%

Current Ratio

12

Quick Ratio

11,5

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium